Quarterly report pursuant to Section 13 or 15(d)

Liquidity and Going Concern (Details Narrative)

v3.20.2
Liquidity and Going Concern (Details Narrative) - USD ($)
6 Months Ended
Jul. 31, 2020
Apr. 07, 2020
Jun. 30, 2020
Jul. 28, 2020
Dec. 31, 2019
Accumulated deficit     $ (260,586,081)   $ (192,823,958)
Cystic Fibrosis Program Related Investment Agreement [Member] | Phase 2 b Clinical trial Member          
Consideration payment milestone received $ 5,000,000   5,000,000    
Proceeds from investments on achieving milestones     $ 25,000,000    
K2 HealthVentures LLC And Ankura Trust Company, LLC [Member] | Loan Agreement [Member] | Subsequent Event [Member]          
Debt face amount       $ 50,000,000  
Market Offering [Member] | Jefferies LLC [Member] | Maximum [Member]          
Number of common stock shares sold   75,000,000